Skip to content

IceCure’s ProSense Offered in Fingers-On Coaching Course at The American Society of Breast Surgeons Breast Follows Ultrasound Course


Skilled coaching programs are well-timed following IceCure’s FDA submitting for advertising authorization of ProSense with breakthrough indication

CAESAREA, Israel, Jan 25, 2023 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Firm”), developer of minimally-invasive cryoablation know-how, the ProSense® System that destroys tumors by freezing, immediately introduced that on January 13-14, 2023the Firm participated within the American Society of Breast Surgeons (“ASBrS”) Breast Fellows Ultrasound Course in Cincinnati, Ohio. The diagnostic and interventional breast ultrasound course was organized by ASBrS.

The course was moderated by Dr. michael berry and Dr. Richard Positive of the West Most cancers Heart in germantown, Tennessee, each investigators in IceCure’s ICE3 ProSense trial in early-stage, low-risk breast most cancers in sufferers who’re at excessive threat to surgical procedure. Dr. Positive led a session of the course on cryoablation of breast tumors with ProSense and performed a hands-on workshop and demonstration.

“ProSense was very effectively obtained by course contributors who received hands-on coaching with our cryoablation system,” said eyal shamir, IceCure’s Chief Government Officer. “We welcome the ASBrS’s function in addressing the necessity to present extra coaching in ultrasound for breast surgeons, as it’s a key talent essential for performing minimally invasive remedies like cryoablation. Clinician coaching is a vital element of IceCure’s multifaceted cooperation with the ASBrS with the purpose of advancing the usual of look after breast most cancers.As we stay up for the FDA’s response to our latest regulatory submitting for advertising authorization, conducting consciousness and coaching round cryoablation for breast procedures helps our business rollout.”

About IceCure Medical Ltd.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, a complicated liquid-nitrogen-based cryoablation remedy for the remedy of tumors (benign and cancerous) by freezing, with the first focus areas being breast, kidney, bone and lung most cancers. Its minimally invasive know-how is a secure and efficient different to hospital surgical tumor elimination that’s simply carried out in a comparatively quick process. The system is marketed and offered worldwide for the indications cleared up to now by the US Meals and Drug Administration (“FDA”) and permitted in Europe with the CE Mark.

Ahead-Trying Statements

This press launch accommodates forward-looking statements throughout the which means of the “secure harbor” provisions of the Personal Securities Litigation Reform Act of 1995 and different US federal securities legal guidelines and Israeli securities legal guidelines. Phrases comparable to “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and comparable expressions or variations of such phrases are meant to determine forward-looking statements. For instance, IceCure is utilizing ahead trying assertion on this press launch when it discusses: trying ahead to the FDA’s response to the Firm’s latest regulatory submitting for advertising authorization of ProSense with breakthrough indication; and the advantages of cryoablation as a remedy for breast most cancers. As a result of such statements take care of future occasions and are primarily based on IceCure’s present expectations, they’re topic to varied dangers and uncertainties and precise outcomes, efficiency or achievements of IceCure may differ materially from these described in or implied by the statements on this press launch. The forward-looking statements contained or implied on this press launch are topic to different dangers and uncertainties, a lot of that are past the management of the Firm, together with these set forth within the Threat Elements part of the Firm’s Annual Report on Kind 20-F for the 12 months ended December 31, 2021filed with the Securities and Change Fee (the “SEC”) on April 1, 2022, as amended, which is obtainable on the SEC’s web site, The Firm undertakes no obligation to replace these statements for revisions or adjustments after the date of this launch, besides as required by legislation. References and hyperlinks to web sites have been offered as a comfort, and the data contained on such web sites is just not integrated by reference into this press launch. The Firm is just not answerable for the contents of third-party web sites.

IR Contact:
Ronen Tsimerman
E mail:

split View authentic content material: follows-ultrasound-course-301730289.html

SOURCE IceCure Medical Ltd


Leave a Reply

Your email address will not be published. Required fields are marked *